Skip to content

Effect of perioperative intravenous infusion of lidocaine on postoperative acute kidney injury in patients with enterogenic sepsis

The effect of lidocaine on sepsis-related kidney injury

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105718
Enrollment
Unknown
Registered
2025-07-09
Start date
2024-01-30
Completion date
Unknown
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

lidocaine group:The loading dose of 1 mg/kg lidocaine was injected intravenously during anesthesia induction, and then intravenous infusion was continued at a rate of 1.5 mg·kg-1·h-1 until the end of

Sponsors

Xinjiang Uygur Autonomous Region People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age>= 18 years old; 2. Patients with intestinal obstruction who intend to undergo exploratory laparotomy under general anesthesia; 3. Meet the diagnostic criteria for sepsis in the 2016 International Sepsis 3.0 Guidelines [14]: For patients with infection or suspected infection, sepsis can be diagnosed when the infection-related organ failure asses (SOFA) score increases by >=2 points from baseline.

Exclusion criteria

Exclusion criteria: 1. Lidocaine intolerance, allergy to lidocaine and other local anesthetics; 2. complete heart block; 3. Pregnant and lactating women; 4. Patients with chronic kidney disease, combined with kidney tumors, urinary tract stones, hydronephrosis, tuberculosis and other kidney diseases; 5. Patients with incomplete clinical data, who or their family members refuse to participate in the trial or refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Incidence of AKI;

Secondary

MeasureTime frame
Serum creatinine;Urea nitrogen;

Countries

China

Contacts

Public ContactLi Qingqing

People's Hospital of Xinjiang Uygur Autonomous Region

1371733488@qq.com+86 131 3991 7083

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026